Intrathecal hydromorphone for chronic nomalignant pain

A retrospective study

Valerie Anderson, Beverly Cooke, Kim Burchiel

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective. Ten percent to 15% of patients with chronic pain experience intolerable side effects or inadequate analgesia with continuous intrathecal morphine therapy. Although clinical experience suggests that rotation to hydromorphone (Dilaudid) can reduce side effects and recapture analgesia, there have been only scattered reports of long-term intrathecal hydromorphone use in patients with nonmalignant pain. The purpose of this study is to review the safety and effectiveness of continuous intrathecal hydromorphone in the management of patients with nonmalignant pain in whom continuous intrathecal morphine therapy has failed. Design. A retrospective review of 37 patients with chronic nonmalignant pain managed with intrathecal hydromorphone after failure of intraspinal morphine. Results. The mean age of patients was 64 years ± 12 SD. All patients suffered from severe nonmalignant pain, most from failed lumbosacral spine operations (19/37; 51%). Morphine was replaced with hydromorphone because of pharmacological complications (21/37; 57%) or inadequate analgesic response (16/37; 43%) after an average of 11 months ± 11 SD of intrathecal therapy. Pharmacological complications, particularly nausea and vomiting, pruritus, and sedation were reduced by hydromorphone in most patients. Peripheral edema was improved by hydromorphone but tended to recur with prolonged hydromorphone exposure. Analgesic response was improved by at least 25% in six of 16 patients who were switched to hydromorphone because of poor pain relief. Conclusions. Hydromorphone can be a safe, analgesic alternative for long-term intrathecal management of nonmalignant pain among patients in whom morphine fails because of pharmacological side effects or inadequate pain relief.

Original languageEnglish (US)
Pages (from-to)287-297
Number of pages11
JournalPain Medicine
Volume2
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Hydromorphone
Chronic Pain
Retrospective Studies
Morphine
Pain
Analgesics
Pharmacology
Analgesia
Pain Management
Pruritus
Nausea
Vomiting
Edema
Spine

Keywords

  • Analgesia
  • Chronic pain
  • Hydromorphone
  • Intrathecal
  • Opioids

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Intrathecal hydromorphone for chronic nomalignant pain : A retrospective study. / Anderson, Valerie; Cooke, Beverly; Burchiel, Kim.

In: Pain Medicine, Vol. 2, No. 4, 2001, p. 287-297.

Research output: Contribution to journalArticle

Anderson, Valerie ; Cooke, Beverly ; Burchiel, Kim. / Intrathecal hydromorphone for chronic nomalignant pain : A retrospective study. In: Pain Medicine. 2001 ; Vol. 2, No. 4. pp. 287-297.
@article{a129882d4a5141af82c85719cae89da2,
title = "Intrathecal hydromorphone for chronic nomalignant pain: A retrospective study",
abstract = "Objective. Ten percent to 15{\%} of patients with chronic pain experience intolerable side effects or inadequate analgesia with continuous intrathecal morphine therapy. Although clinical experience suggests that rotation to hydromorphone (Dilaudid) can reduce side effects and recapture analgesia, there have been only scattered reports of long-term intrathecal hydromorphone use in patients with nonmalignant pain. The purpose of this study is to review the safety and effectiveness of continuous intrathecal hydromorphone in the management of patients with nonmalignant pain in whom continuous intrathecal morphine therapy has failed. Design. A retrospective review of 37 patients with chronic nonmalignant pain managed with intrathecal hydromorphone after failure of intraspinal morphine. Results. The mean age of patients was 64 years ± 12 SD. All patients suffered from severe nonmalignant pain, most from failed lumbosacral spine operations (19/37; 51{\%}). Morphine was replaced with hydromorphone because of pharmacological complications (21/37; 57{\%}) or inadequate analgesic response (16/37; 43{\%}) after an average of 11 months ± 11 SD of intrathecal therapy. Pharmacological complications, particularly nausea and vomiting, pruritus, and sedation were reduced by hydromorphone in most patients. Peripheral edema was improved by hydromorphone but tended to recur with prolonged hydromorphone exposure. Analgesic response was improved by at least 25{\%} in six of 16 patients who were switched to hydromorphone because of poor pain relief. Conclusions. Hydromorphone can be a safe, analgesic alternative for long-term intrathecal management of nonmalignant pain among patients in whom morphine fails because of pharmacological side effects or inadequate pain relief.",
keywords = "Analgesia, Chronic pain, Hydromorphone, Intrathecal, Opioids",
author = "Valerie Anderson and Beverly Cooke and Kim Burchiel",
year = "2001",
doi = "10.1046/j.1526-4637.2001.01052.x",
language = "English (US)",
volume = "2",
pages = "287--297",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Intrathecal hydromorphone for chronic nomalignant pain

T2 - A retrospective study

AU - Anderson, Valerie

AU - Cooke, Beverly

AU - Burchiel, Kim

PY - 2001

Y1 - 2001

N2 - Objective. Ten percent to 15% of patients with chronic pain experience intolerable side effects or inadequate analgesia with continuous intrathecal morphine therapy. Although clinical experience suggests that rotation to hydromorphone (Dilaudid) can reduce side effects and recapture analgesia, there have been only scattered reports of long-term intrathecal hydromorphone use in patients with nonmalignant pain. The purpose of this study is to review the safety and effectiveness of continuous intrathecal hydromorphone in the management of patients with nonmalignant pain in whom continuous intrathecal morphine therapy has failed. Design. A retrospective review of 37 patients with chronic nonmalignant pain managed with intrathecal hydromorphone after failure of intraspinal morphine. Results. The mean age of patients was 64 years ± 12 SD. All patients suffered from severe nonmalignant pain, most from failed lumbosacral spine operations (19/37; 51%). Morphine was replaced with hydromorphone because of pharmacological complications (21/37; 57%) or inadequate analgesic response (16/37; 43%) after an average of 11 months ± 11 SD of intrathecal therapy. Pharmacological complications, particularly nausea and vomiting, pruritus, and sedation were reduced by hydromorphone in most patients. Peripheral edema was improved by hydromorphone but tended to recur with prolonged hydromorphone exposure. Analgesic response was improved by at least 25% in six of 16 patients who were switched to hydromorphone because of poor pain relief. Conclusions. Hydromorphone can be a safe, analgesic alternative for long-term intrathecal management of nonmalignant pain among patients in whom morphine fails because of pharmacological side effects or inadequate pain relief.

AB - Objective. Ten percent to 15% of patients with chronic pain experience intolerable side effects or inadequate analgesia with continuous intrathecal morphine therapy. Although clinical experience suggests that rotation to hydromorphone (Dilaudid) can reduce side effects and recapture analgesia, there have been only scattered reports of long-term intrathecal hydromorphone use in patients with nonmalignant pain. The purpose of this study is to review the safety and effectiveness of continuous intrathecal hydromorphone in the management of patients with nonmalignant pain in whom continuous intrathecal morphine therapy has failed. Design. A retrospective review of 37 patients with chronic nonmalignant pain managed with intrathecal hydromorphone after failure of intraspinal morphine. Results. The mean age of patients was 64 years ± 12 SD. All patients suffered from severe nonmalignant pain, most from failed lumbosacral spine operations (19/37; 51%). Morphine was replaced with hydromorphone because of pharmacological complications (21/37; 57%) or inadequate analgesic response (16/37; 43%) after an average of 11 months ± 11 SD of intrathecal therapy. Pharmacological complications, particularly nausea and vomiting, pruritus, and sedation were reduced by hydromorphone in most patients. Peripheral edema was improved by hydromorphone but tended to recur with prolonged hydromorphone exposure. Analgesic response was improved by at least 25% in six of 16 patients who were switched to hydromorphone because of poor pain relief. Conclusions. Hydromorphone can be a safe, analgesic alternative for long-term intrathecal management of nonmalignant pain among patients in whom morphine fails because of pharmacological side effects or inadequate pain relief.

KW - Analgesia

KW - Chronic pain

KW - Hydromorphone

KW - Intrathecal

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=0035696752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035696752&partnerID=8YFLogxK

U2 - 10.1046/j.1526-4637.2001.01052.x

DO - 10.1046/j.1526-4637.2001.01052.x

M3 - Article

VL - 2

SP - 287

EP - 297

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 4

ER -